Onco Actu du 26 janvier 2016

	1. Biologie
Gene often lost in childhood cancer crucial in cells' life or death decision [Karolinska Institutet] "Our data strongly suggest that KIF1Bβ, which is localised on chromosome 1p36, might be such a neuroblastoma tumour suppressor gene."
	2. Etiologie
Unraveling the Ties of Altitude, Oxygen and Lung Cancer [NY Times] Epidemiologists have long been puzzled by a strange pattern in their data: People living at higher altitudes appear less likely to get lung cancer.
	3.1 Tabac
Teens who vape are more likely to later try real cigarettes [STAT] In the study, Wills followed more than 2,000 Hawaiian high school students for a year.
Cancer Research UK urges government to make big tobacco cough up [Cancer Research UK] The charity is launching a new “Cough Up” campaign, and wants the public to support a simple solution to the problem – making the tobacco industry pay for public health services and mass media quit campaigns to help save thousands of lives.
Teenagers who use e-cigarettes 'more likely to take up smoking', study finds [The Telegraph] Just under a third of more than 2,300 students had used e-cigarettes when they were first questioned in 2013 at the age of 14, the study published in the journal Tobacco Control found.
Teen vaping leads to teen smoking, new study suggests [LA Times] The results showed that among students who had never smoked in 2013, the risk of at least trying a cigarette by 2014 was 5% for those who hadn’t vaped and 14% for those who had.
	4.10 Dép., diag. & prono. - FDA, EMA, NICE,...
Dako, an Agilent Technologies Company, Announces Expanded FDA Approval of Complementary Diagnostic Test to Include Melanoma [Dako] The complementary test has now been expanded to include melanoma and may be used by physicians to determine PD-L1 status. Positive PD-L1 status in melanoma has been correlated with the magnitude of treatment effect on progression-free survival from OPDIVO® (nivolumab), from Bristol-Myers Squibb.
	4.12 Biopsies liquides
Are We Ready for a Blood Test for Cancer? [UCSF] Liquid Biopsy Shows Promise, Researchers Say, but Techniques Still Need More Development.
	4.2 Dép., diag. & prono. - Génome
The genomics revolution and why we need to be smarter in our use of genetic data [The Institute of Cancer Research] Professor Rahman explained that current approaches to analysing data rely on scaling up our existing methods, and simply cannot cope with the enormous increase in flow.
	5.2 Pharma
US 'orphan status' for Immunocore's eye cancer drug [PharmaTimes] The firm is hoping that IMCgp100, its most advanced ImmTAC (Immune mobilising mTCR Against Cancer), will offer patients the first treatment for the debilitating condition, and says the orphan drug designation gives it the opportunity to fast-track the programme.
	5.2.1 Pharma - Partenariats
Broad Institute Genomic Services partners with Takeda Pharmaceuticals to offer genomic insight into the recently approved therapeutic NINLARO® (ixazomib) [Broad Institute of MIT and Harvard] Data generated from the analysis are expected to expand the understanding of multiple myeloma biology and potentially identify mechanisms of sensitivity or resistance to proteasome inhibitor treatment, which will inform and improve future therapies.
Merck, Affimed to test Hodgkin lymphoma combo [Pharma Times] Under the deal, Affimed will fund and conduct a Phase Ib clinical trial to assess the potential of combining Merck's anti-PD-1 therapy Keytruda (pembrolizumab) with Affimed's experimental AFM13 for the treatment of patients whose disease has relapsed or is refractory to chemotherapy.
	5.2.3 Pharma - économie
Big Pharma’s worst nightmare [The Guardian] Jamie Love has spent years battling global drug companies, unshakable in his belief that even the world’s poorest people should have access to life-saving medicines. Is it time that our own government listened to him?
Soon-Shiong's NantCell raises another $57M for immuno-oncology work [FierceBiotech] Like most of Soon-Shiong's many biotech ventures, NantCell has provided little detail on its specific goals, and the company didn't respond to a request for comment Monday.
OncoMed Shares Fall After Discouraging News on Pancreatic Cancer Drug [Xconomy] OncoMed develops antibody drugs that target proteins on cancer stem cells—a subset of tumor cells that can renew themselves and cause tumors to regrow despite treatment. Tarextumab and demcizumab are two of the first drugs to come from that work.
	5.3.4 Traitements - AMM (FDA, EMA)
BMS' Opdivo evens the score in melanoma with two new FDA green lights [FiercePharma] The two-drug regimen made its debut at $141,000 for a four-dose course of treatment, $256,000 for a full year's worth of therapy.
	5.5 ASCO
Little Benefit With Targeted Tx in GI Cancers [Medpage Today] Trials of Zaltrap and Kadcyla miss mark.
	6. Lutte contre les cancers
NCI-Match extends pause in enrollment [BioCentury] According to NCI's ECOG-ACRIN group, the delay will allow the study's leaders to expand laboratory capabilities to accommodate the volume and pace of patient enrollment, add treatment arms and complete a scientific review of data from the first set of patients.
Grand Challenge six: target cancer’s ‘super-controller’ [Cancer Research UK] At the heart of this challenge lies a molecule called MYC. In the same way that a conductor directs all the various parts of an orchestra to work together in harmony, MYC co-ordinates the actions of many different genes inside cells to keep things running smoothly.
	6.6 Publications
Top journal editors resist transparency [HealthNewsReview] Journal editors certainly have conflicted interests of their own, an obvious one being the huge revenues generated by pharmaceutical company ads and reprints. One is hard pressed to find evidence showing transparency and sharing in science to be a bad thing for anyone without marketing interests.
Journal Editors To Researchers: Show Everyone Your Clinical Data [NPR] There are many details to resolve. How will sharing work? Who will pay for it? How will the researchers who produced the work get credit in the subsequent analyses? All good and difficult questions, but it is high time to find solutions.
	6.7 DMP, Big Data & applis
Big Pharma's bet on Big Data creates opportunities and risks [Reuters] This kind of new medical technology is designed to allow patients to keep track of their drug usage on their smartphones or tablets and for their doctors to instantly access the data over the web to monitor their condition.
	6.7.2 Applis
EU Looks to Improve Data Quality of mHealth Apps [RAPS] The European Commission is bringing together a working group to develop guidelines by the end of 2016 for assessing the validity and reliability of the data that mobile health (mHealth) applications collect and process in order to make these ubiquitous apps more useful for public health.
	6.9 Controverses
Could Harvard Medical School sell its naming rights for $1b? [STAT] “To meet our strategic vision of going forward into the future at the highest level, we need the money,” said Dr. Lee Nadler, Harvard Med’s dean for clinical and translational research. “We need to find a billion-dollar donor.”